To evaluate ADAM23 expression in CNS tumors, we measured ADAM23 mRNA levels using qRT-PCR in the non-neoplastic brain (NNB) and 143 WHO Grades 2–4 astrocytomas from the HC cohort. The gene discussed is ADAM23; the disease is central nervous system neoplasm.